As expected, weak SMARCB1 expression has been recognized as a diagnostic biomarker in several tumors including epithelioid sarcoma, rhabdoid tumor, synovial sarcoma, and pediatric poorly differentiated chordoma [15,16,19]. This evidence concerns the gene SMARCB1 and rhabdoid tumor.